Flagship Ventures Fund IV General Partner’s Editas Medicine EDIT Stock Holding History

Flagship Ventures Fund IV General Partner’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$121M	Buy	+4,955,316	New	+$167M	20.67%	2

Other funds holding EDIT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVMCV

Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Flagship Ventures Fund IV General Partner's EDIT Position: Q2 2016 in Review

Flagship Ventures Fund IV General Partner opened a new position in Editas Medicine (EDIT) in Q2 2016: 4,955,316 shares worth $121M. The stake represents 20.67% of the portfolio and ranks #2 among its holdings.

68 funds tracked by Wall St. Rank hold EDIT as of Q2 2016.

Flagship Ventures Fund IV General Partner held 4,955,316 shares of Editas Medicine worth $121M as of Q2 2016.
Editas Medicine was a new Flagship Ventures Fund IV General Partner position in Q2 2016.
Editas Medicine made up 20.67% of Flagship Ventures Fund IV General Partner's portfolio in Q2 2016, its #2 holding.
68 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2016.

Based on Flagship Ventures Fund IV General Partner's 13F filing for Q2 2016, filed 15 Aug 2016.